Patents Assigned to Hexal AG
-
Patent number: 9717707Abstract: The invention relates to a pharmaceutical composition, comprising or consisting of: 10 to 30 weight percent of at least a pharmaceutically active amount of a pharmaceutical substance selected from the group comprising statins, in particular water-insoluble, oxidatively degradable statins, preferably cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combinations thereof, 30 to 70 weight percent of lactose hydrate, 2 to 15 weight percent of microcrystalline cellulose, 5 to 25 weight percent of a partially water-soluble starch, 0.2 to 4 weight percent of at least one alkali and/or alkaline-earth salt of stearic acid and/or stearyl fumaric acid, wherein the composition contains no antioxidatively active substances such as chain terminators, reductants, free-radical scavengers, and complexing agents.Type: GrantFiled: December 6, 2012Date of Patent: August 1, 2017Assignee: HEXAL AGInventors: Theresa Taeubrich, Patrick Rother
-
Publication number: 20170205423Abstract: The present invention relates to a method for analyzing glycans of a recombinant glycoprotein in a liquid sample of a mammal. Specifically the method comprises a step of affinity purifying the recombinant glycoprotein from the sample, enzymatically releasing a glycan containing fragment from the immobilized glycoprotein, adding a reference standard containing isotopically labeled glycans, fluorescently label the glycans and analyzing the glycans using LC-MS. The present invention also relates to a method further comprising analyzing the glycans of the immobilized recombinant glycoprotein fragment, further comprising a pre-clearing step of the liquid sample, and releasing the glycans from the immobilized recombinant glycoprotein fragment.Type: ApplicationFiled: July 17, 2015Publication date: July 20, 2017Applicant: Hexal AGInventors: Fabian Higel, Andreas Seidl, Uwe Demelbauer
-
Publication number: 20170182034Abstract: The present invention relates to a solid oral pharmaceutical composition comprising vortioxetine hydrobromide in a matrix formed from at least one polyethylene oxide and optionally one or more further matrix forming polymers.Type: ApplicationFiled: December 21, 2016Publication date: June 29, 2017Applicant: Hexal AGInventors: Andreas Krekeler, Dimitri Neumann, Michael Sedlmayr
-
Patent number: 9592296Abstract: The invention relates to a pharmaceutical composition for oral administration comprising or consisting of (i) 10 to 30% weight, of at least one pharmaceutically active substance selected from the group consisting of water-soluble, oxidatively-degradable statins, preferably atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination thereof, (ii) 0.01 to 3% weight, of a first anti-oxidatively active substance (A1), (iii) 0.01 to 3% weight, of a second anti-oxidatively active substance (A2) that differs from the first anti-oxidatively active substance (A1), and (iv) 60 to 85% weight of at least one additive, selected from the group consisting of filler, binder, flow-regulating agent, disintegrant and anti-blocking agent or a combination thereof, and the use of the pharmaceutical composition in medicine.Type: GrantFiled: August 21, 2012Date of Patent: March 14, 2017Assignee: HEXAL AGInventors: Theresa Taeubrich, Patrick Rother
-
Patent number: 9480743Abstract: The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof.Type: GrantFiled: December 28, 2011Date of Patent: November 1, 2016Assignee: Hexal AGInventors: Martina Danek-Bulius, Britta Deutel, Sabine Fürtinger, Bernt Pragl, Drago Kuzman
-
Publication number: 20160018409Abstract: The use of anthranilic acid (2-AA) to label N-glycans prior to separation using a reversed-phase liquid chromatography (RP-LC) column under acidic conditions using formic acid is described herein. Negatively charged 2-AA offers stronger retention on the reversed phase column than 2-aminobenzamide (2-AB) in RP-LC and allows efficient ionization and detection of 2-AA labeled N-glycans. The acidic conditions used for the RP-LC leads to an efficient separation of acidic 2-AA N-glycans carrying terminal sialylation without the need for an ion-pairing reagent. The method and compositions described herein may be used with RP-nano-LC-MS and a 96-well plate sample preparation, which allows attomolar sensitivity and high throughput.Type: ApplicationFiled: October 17, 2013Publication date: January 21, 2016Applicant: HEXAL AGInventor: Fabian Higel
-
Patent number: 9211265Abstract: The present invention is directed to a tablet comprising at least one bitter tasting and/or mucosa numbness causing pharmaceutically active compound; and at least one zinc salt. In addition, the present invention relates to the use of a zinc salt to reduce or mask the bitter taste of or the numbness of the mucosa caused by pharmaceutically active compounds.Type: GrantFiled: April 12, 2010Date of Patent: December 15, 2015Assignee: HEXAL AGInventor: Klaus Storm
-
Publication number: 20140328936Abstract: The invention relates to a pharmaceutical composition, comprising or consisting of: 10 to 30 weight percent of at least a pharmaceutically active amount of a pharmaceutical substance selected from the group comprising statins, in particular water-insoluble, oxidatively degradable statins, preferably cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combinations thereof, 30 to 70 weight percent of lactose hydrate, 2 to 15 weight percent of microcrystalline cellulose, 5 to 25 weight percent of a partially water-soluble starch, 0.2 to 4 weight percent of at least one alkali and/or alkaline-earth salt of stearic acid and/or stearyl fumaric acid, wherein the composition contains no antioxidatively active substances such as chain terminators, reductants, free-radical scavengers, and complexing agents.Type: ApplicationFiled: December 6, 2012Publication date: November 6, 2014Applicant: HEXAL AGInventors: Theresa Taeubrich, Patrick Rother
-
Publication number: 20140323986Abstract: The present invention relates to a method of producing syringes. Said method comprises fixing a needle to a syringe body by use of an adhesive followed by subjecting the syringes thus obtained to heat treatment. The invention further relates to a method of reducing leachables and/or extractables in prefilled syringes, said method comprising heat treating pre-fabricated syringes at a temperature of at least 40° C. before filling.Type: ApplicationFiled: May 13, 2014Publication date: October 30, 2014Applicant: Hexal AGInventor: Peter Skufca
-
Publication number: 20140227355Abstract: The invention relates to a pharmaceutical composition for oral administration comprising or consisting of (i) 10 to 30% weight, of at least one pharmaceutically active substance selected from the group consisting of water-soluble, oxidatively-degradable statins, preferably atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin or a combination thereof, (ii) 0.01 to 3% weight, of a first anti-oxidatively active substance (A1), (iii) 0.01 to 3% weight, of a second anti-oxidatively active substance (A2) that differs from the first anti-oxidatively active substance (A1), and (iv) 60 to 85% weight of at least one additive, selected from the group consisting of filler, binder, flow-regulating agent, disintegrant and anti-blocking agent or a combination thereof, and the use of the pharmaceutical composition in medicine.Type: ApplicationFiled: August 21, 2012Publication date: August 14, 2014Applicant: HEXAL AGInventors: Theresa Taeubrich, Patrick Rother
-
Patent number: 8785431Abstract: The present invention relates to diester prodrugs of cilazaprilate which undergo enzymatic cleavage to release the active metabolite cilazaprilate that is used for the treatment of hypertension and congestive heart failure. Furthermore the diester prodrugs of cilazaprilate possess all the properties necessary to be topically administered, preferably via transdermal therapeutic systems.Type: GrantFiled: June 20, 2012Date of Patent: July 22, 2014Assignee: Hexal AGInventors: Günther Bernhardt, Miriam Ertel, Armin Buschauer, Jörg Nink
-
Publication number: 20140147477Abstract: The present invention relates to diester prodrugs of cilazaprilate which undergo enzymatic cleavage to release the active metabolite cilazaprilate that is used for the treatment of hypertension and congestive heart failure. Furthermore the diester prodrugs of cilazaprilate possess all the properties necessary to be topically administered, preferably via transdermal therapeutic systems.Type: ApplicationFiled: June 20, 2012Publication date: May 29, 2014Applicant: HEXAL AGInventors: Günther Bernhardt, Miriam Ertel, Armin Buschauer, Jörg Nink
-
Patent number: 8722090Abstract: The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.Type: GrantFiled: December 11, 2003Date of Patent: May 13, 2014Assignee: Hexal AGInventors: Karin Klokkers, Ina Elfriede Otto, Heidemarie Edith Elfriede Meyer
-
Patent number: 8720165Abstract: The present invention relates to a method of producing syringes. Said method comprises fixing a needle to a syringe body by use of an adhesive followed by subjecting the syringes thus obtained to heat treatment. The invention further relates to a method of reducing leachables and/or extractables in prefilled syringes, said method comprising heat treating pre-fabricated syringes at a temperature of at least 40° C. before filling.Type: GrantFiled: May 20, 2009Date of Patent: May 13, 2014Assignee: Hexal AGInventor: Peter Skufca
-
Publication number: 20130336968Abstract: The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof.Type: ApplicationFiled: December 28, 2011Publication date: December 19, 2013Applicant: HEXAL AGInventors: Martina Danek-Bulius, Britta Deutel, Sabine Furtinger, Bernt Pragl, Drago Kuzman
-
Publication number: 20130331803Abstract: The invention is concerned with a transdermal therapeutic system (TTS) comprising buprenorphine and a method of manufacturing such a TTS. The transdermal therapeutic system is used for the transdermal administration of buprenorphine and analogues thereof. In particular, the invention relates to the use of a transdermal therapeutic system (TTS) for analgesic purposes. The TTS according to the invention comprises a transdermal drug delivery composition comprising buprenorphine and an adhesive component, which is a mixture of a crosslinked and a non-crosslinked acrylic polymer and a penetration enhancer comprising a keto acid.Type: ApplicationFiled: November 17, 2010Publication date: December 12, 2013Applicant: HEXAL AGInventors: Jens Fleschhut, Susanne Feinaeugle, Karin Lauer
-
Publication number: 20130217697Abstract: The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agent(s).Type: ApplicationFiled: October 27, 2011Publication date: August 22, 2013Applicant: HEXAL AGInventors: Thomas Kohr, Petra Obermeier
-
Publication number: 20130216594Abstract: The invention relates to a process for preparing a composition, more particularly a pharmaceutical composition for oral administration, comprising the steps of forming a suspension of at least one pharmaceutical ingredient and a solvent or solvent mixture, the at least one pharmaceutical ingredient being insoluble or poorly soluble in the solvent or solvent mixture, the step of adding at least one gel former to the suspension, the at least one gel former being swellable in the solvent or solvent mixture, and, optionally, the step of swelling the suspension.Type: ApplicationFiled: October 27, 2011Publication date: August 22, 2013Applicant: HEXAL AGInventors: Andreas Krekeler, Dimitri Neumann
-
Patent number: 8501056Abstract: The invention relates to a method for the solvent-free preparation of a homogenizate, especially for implants or microparticles, wherein one or more polymers and one or more active constituents, as raw materials, are homogenized together below the glass transition temperature of the polymer(s) and, when homogenization is complete, brought to room temperature.Type: GrantFiled: May 23, 2002Date of Patent: August 6, 2013Assignee: Hexal AGInventors: Gregor Schütz, Brigitte Freudensprung
-
Publication number: 20120220628Abstract: The present invention is directed to a tablet comprising at least one bitter tasting and/or mucosa numbness causing pharmaceutically active compound; and at least one zinc salt. In addition, the present invention relates to the use of a zinc salt to reduce or mask the bitter taste of or the numbness of the mucosa caused by pharmaceutically active compounds.Type: ApplicationFiled: April 12, 2010Publication date: August 30, 2012Applicant: HEXAL AGInventor: Klaus Storm